Genetic Variation Affects Colorectal Cancer Risk with Aspirin, NSAIDs
Two single nucleotide polymorphisms have been identified which confer benefit for aspirin or NSAID use in relation to colorectal cancer risk.
Two single nucleotide polymorphisms (SNPs) have been identified which confer differential benefit for aspirin and/or nonsteroidal anti-inflammatory drug (NSAID) use in relation to colorectal cancer risk, according to a study published in the Journal of the American Medical Association.
Hongmei Nan, M.D., Ph.D., from Indiana University in Indianapolis, and colleagues conducted a case-control study using data from studies involving 8,634 colorectal cancer cases and 8,553 matched controls.
The authors tested gene × environment interactions between regular use of aspirin and/or NSAIDs and SNPs in relation to colorectal cancer risk.
The researchers found that, compared with non-regular use, regular use of aspirin and/or NSAIDs correlated with reduced risk of colorectal cancer (odds ratio [OR], 0.69).
There was a genome-wide significant interaction with aspirin and/or NSAID use at the SNP rs2965667 at chromosome 12p12.3; aspirin and/or NSAID use correlated with lower risk of colorectal cancer for individuals with rs2965667-TT genotype (OR, 0.66), while a higher risk was seen among those with rare TA or AA genotypes (OR, 1.89).
There was a genome-wide significant interaction with use of aspirin and/or NSAIDs with the SNP rs16973225 at chromosome 15q25.2; regular use correlated with lower risk for those with the AA genotype (OR, 0.66), while no association was seen for those with AC or CC genotypes (OR, 0.97; P = 0.76).
"Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies," the authors write.
One author disclosed holding a patent for aspirin as a colorectal chemopreventive agent; one author disclosed financial ties to the pharmaceutical industry.